EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study

Wei Guo, Xuejun Wen, Yuhang Chen, Tianzhi Zhao, Jia Liu, Yucen Tao, Hao Fu, Hongjian Wang, Weizhi Xu, Yizhen Pang, Liang Zhao, Jingxiong Huang und 6 weitere

Acta Pharmaceutica Sinica B · 2025-02 · 15 (2) · 707-721

DOI: 10.1016/j.apsb.2024.05.022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-02. Verfasst von Wei Guo und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, the First Affiliated Hospital of Xiamen Universi…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peptide receptor radionuclide therapy (PRRT) with radiolabeled SSTR2 agonists is a treatment option that is highly effective in controlling metastatic and progressive neuroendocrine tumors (NETs). Previous studies have shown that an SSTR2 agonist combined with albumin binding moiety Evans blue (denoted as 177Lu-EB-TATE) is characterized by a higher tumor uptake and residence time in preclinical models and in patients with metastatic NETs. This study aimed to enhance the in vivo stability, pharmacokinetics, and pharmacodynamics of 177Lu-EB-TATE by replacing the maleimide-thiol group with a polyethylene glycol chain, resulting in a novel EB conjugated SSTR2-targeting radiopharmaceutical, 177Lu-LNC1010, for PRRT. In preclinical studies, 177Lu-LNC1010 exhibited good stability and SSTR2-binding affinity in AR42J tumor cells and enhanced uptake and prolonged retention in AR42J tumor xenografts. Thereafter, we presented the first-in-human dose escalation study of 177Lu-LNC1010 in patients with advanced/metastatic NETs. 177Lu-LNC1010 was well-tolerated by all patients, with minor adverse effects, and exhibited significant uptake and prolonged retention in tumor lesions, with higher tumor radiation doses than those of 177Lu-EB-TATE. Preliminary PRRT efficacy results showed an 83% disease control rate and a 42% overall response rate after two 177Lu-LNC1010 treatment cycles. These encouraging findings warrant further investigations through multicenter, prospective, and randomized controlled trials.

Schlagwörter

Stichwörter der Autor:innen

177Lu-LNC1010Evans blueFirst-in-human dose escalation studyNeuroendocrine tumorPeptide receptor radionuclide therapyRadiolabeled somatostatin analog

Autor:innen und Institutionen

  • Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361102, China.
  • School of Clinical Medicine, Fujian Medical University, Fuzhou 350005, China.
  • State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China.
  • Departments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, S…
  • Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 138667, Singapore.
  • Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 138667, Singapore.

Zitieren

APA

Guo, W., Wen, X., Chen, Y., Zhao, T., Liu, J., Tao, Y., Fu, H., Wang, H., Xu, W., Pang, Y., Zhao, L., Huang, J., Xu, P., Guo, Z., Miao, W., Zhang, J., Chen, X., & Chen, H. (2025). Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study. Acta Pharmaceutica Sinica B, 15(2), 707-721. https://doi.org/10.1016/j.apsb.2024.05.022

Vancouver

Guo W, Wen X, Chen Y, Zhao T, Liu J, Tao Y, et al. Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study. Acta Pharmaceutica Sinica B. 2025;15(2):707-721. doi:10.1016/j.apsb.2024.05.022

BibTeX
@article{Guo2025,
  author = {Guo, Wei and Wen, Xuejun and Chen, Yuhang and Zhao, Tianzhi and Liu, Jia and Tao, Yucen and Fu, Hao and Wang, Hongjian and Xu, Weizhi and Pang, Yizhen and Zhao, Liang and Huang, Jingxiong and Xu, Pengfei and Guo, Zhide and Miao, Weibing and Zhang, Jingjing and Chen, Xiaoyuan and Chen, Haojun},
  title = {Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2025},
  volume = {15},
  number = {2},
  pages = {707--721},
  doi = {10.1016/j.apsb.2024.05.022}
}
Kostenlos starten →